Clinical Trial Update: Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL [Phase 2]

View source ↗

Summary

A Phase 2 trial of rituximab in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma (Burkitt lymphoma) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Burkitt Lymphoma | Phase 2 | Status: TERMINATED